John K. Bakewell - 19 May 2026 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Director
Issuer ticker: TMCI
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 21:00:11 UTC
Prior SEC filing: 18 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for John Bakewell

Key filing fact

John K. Bakewell filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 19 May 2026.

Key facts

This page summarizes John K. Bakewell's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 21:00.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001183553 Primary reporting owner

BAKEWELL JOHN K

Relationship: Director
Address: C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA BEACH
Signature: /s/ Lisa Taylor as Attorney-in-fact for John Bakewell
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +17%
Price: $0.000000^*
Shares after: 204,056
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

TMCI holding

Common Sotck

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 250,000
Date: 19 May 2026
Ownership: By spouse as trustee of a trust

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,300
Date: 19 May 2026
Ownership: As trustee of a trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date.

Footnote F2

Includes 30,000 restricted stock units.